FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954906312> ?p ?o ?g. }

• W2954906312 endingPage "159" @default.
• W2954906312 startingPage "150" @default.
• W2954906312 abstract "Background. P-glycoprotein (Pgp, ABCB1-protein) is a membrane transporter with broad substrate specificity that is localized in hepatocytes, enterocytes, epithelial renal tubules, and also in tissue barriers, including blood-brain barrier (BBB). Increased Pgp activity in BBB is one of the reasons for the pharmacoresistance of a number of CNS diseases.&#x0D; Aim. Analysis of Pgp functional activity in BBB during experimental Parkinson's syndrome.&#x0D; Materials and Methods. The work was performed on 90 Wistar rats, divided into 3 series (n=30 in each). The 1 series (control) was subcutaneously injected sunflower oil once a day for 7 days, and Pgp activity in BBB was assessed on the 8th day. The 2 and 3 series (pathology control) - were administered rotenone at a dose of 2.5 mg/kg once a day for 7 and 28 days respectively to simulate parkin-sonism. At the end of the experiment Pgp activity was estimated. To confirm Parkinson's syndrome, in addition to the clinical picture, level of dopamine in midbrain and striatum was determined using enzyme-linked immunosorbent assay. Pgp functional activity in BBB was assessed by the degree of penetration of its marker substrate fexofenadine into the brain after its intravenous administration at a dose of 10 mg/kg. The content of fexofenadine in the blood plasma and in brain tissue was estimated by the area under pharmacokinetic curve of the substance (in the blood or brain tissues) - AUC0-t(plasma) or AUC0-t(brain) respectively. To assess the BBB permeability the ratio AUC0-t(brain) / AUC0-t(plasma) was calculated.&#x0D; Results. Rotenone administration led to the development of parkinsonism typical picture: muscle stiffness, hypokinesia, gait instability. There was a decrease in dopamine level in the striatum after 7 days by 69.6% (p=0.095), after 28 days - by 93.9% (p=0.008), in midbrain - by 72.7% (p=0.095) and 68.7% (p=0.032) respectively. Fexofenadine AUC0-t(plasma) and AUC0-t(brain) after its intravenous administration to control rats were 266.2 (246.4; 285.6) μg/ml*min and 5.9 (5.8;6.6) µg/g*min respectively, AUC0-t(brain) /AUC0-t(plasma) - 0.020 (0.019; 0.022). When rotenone was for 7 days administered - fexofenadine AUC0-t(brain) increased 2.02 times (p=0.0163), AUC0-t(brain) / AUC0-t(plasma) - 2.4 times (p=0.0283). 28 days administration of rotenone led to augmentation of AUC0-t(brain) of fexofenadine by 1.75 times (p=0.0283), AUC0-t(brain) / AUC0-t(plasma) - by 2.27 times (p=0.0163).&#x0D; Conclusions. The development of Parkinson’s syndrome, caused by the administration of rotenone, inhibits Pgp functional activity in BBB, which is confirmed by the accumulation in the brain marker substrate of the transporter - fexofenadine." @default.
• W2954906312 created "2019-07-12" @default.
• W2954906312 creator A5002804252 @default.
• W2954906312 creator A5005087853 @default.
• W2954906312 creator A5009505567 @default.
• W2954906312 creator A5021110333 @default.
• W2954906312 creator A5024722857 @default.
• W2954906312 creator A5030106697 @default.
• W2954906312 creator A5060117263 @default.
• W2954906312 date "2019-07-02" @default.
• W2954906312 modified "2023-09-23" @default.
• W2954906312 title "Functional activity of p-glycoprotein in blood-brain barrier during experimental par-kinson's syndrome" @default.
• W2954906312 cites W2001097099 @default.
• W2954906312 cites W2001408101 @default.
• W2954906312 cites W2018135223 @default.
• W2954906312 cites W2023151425 @default.
• W2954906312 cites W2029503022 @default.
• W2954906312 cites W2030504165 @default.
• W2954906312 cites W2035248522 @default.
• W2954906312 cites W2046632451 @default.
• W2954906312 cites W2077085855 @default.
• W2954906312 cites W2093221129 @default.
• W2954906312 cites W2119717989 @default.
• W2954906312 cites W2316522881 @default.
• W2954906312 cites W2343807299 @default.
• W2954906312 cites W2484686817 @default.
• W2954906312 doi "https://doi.org/10.23888/pavlovj2019272150-159" @default.
• W2954906312 hasPublicationYear "2019" @default.
• W2954906312 type Work @default.
• W2954906312 sameAs 2954906312 @default.
• W2954906312 citedByCount "1" @default.
• W2954906312 countsByYear W29549063122023 @default.
• W2954906312 crossrefType "journal-article" @default.
• W2954906312 hasAuthorship W2954906312A5002804252 @default.
• W2954906312 hasAuthorship W2954906312A5005087853 @default.
• W2954906312 hasAuthorship W2954906312A5009505567 @default.
• W2954906312 hasAuthorship W2954906312A5021110333 @default.
• W2954906312 hasAuthorship W2954906312A5024722857 @default.
• W2954906312 hasAuthorship W2954906312A5030106697 @default.
• W2954906312 hasAuthorship W2954906312A5060117263 @default.
• W2954906312 hasConcept C112705442 @default.
• W2954906312 hasConcept C126322002 @default.
• W2954906312 hasConcept C133936738 @default.
• W2954906312 hasConcept C134018914 @default.
• W2954906312 hasConcept C185592680 @default.
• W2954906312 hasConcept C2776711289 @default.
• W2954906312 hasConcept C2778402981 @default.
• W2954906312 hasConcept C2778707650 @default.
• W2954906312 hasConcept C2780062018 @default.
• W2954906312 hasConcept C501593827 @default.
• W2954906312 hasConcept C513476851 @default.
• W2954906312 hasConcept C529278444 @default.
• W2954906312 hasConcept C55493867 @default.
• W2954906312 hasConcept C71924100 @default.
• W2954906312 hasConcept C98274493 @default.
• W2954906312 hasConceptScore W2954906312C112705442 @default.
• W2954906312 hasConceptScore W2954906312C126322002 @default.
• W2954906312 hasConceptScore W2954906312C133936738 @default.
• W2954906312 hasConceptScore W2954906312C134018914 @default.
• W2954906312 hasConceptScore W2954906312C185592680 @default.
• W2954906312 hasConceptScore W2954906312C2776711289 @default.
• W2954906312 hasConceptScore W2954906312C2778402981 @default.
• W2954906312 hasConceptScore W2954906312C2778707650 @default.
• W2954906312 hasConceptScore W2954906312C2780062018 @default.
• W2954906312 hasConceptScore W2954906312C501593827 @default.
• W2954906312 hasConceptScore W2954906312C513476851 @default.
• W2954906312 hasConceptScore W2954906312C529278444 @default.
• W2954906312 hasConceptScore W2954906312C55493867 @default.
• W2954906312 hasConceptScore W2954906312C71924100 @default.
• W2954906312 hasConceptScore W2954906312C98274493 @default.
• W2954906312 hasIssue "2" @default.
• W2954906312 hasLocation W29549063121 @default.
• W2954906312 hasOpenAccess W2954906312 @default.
• W2954906312 hasPrimaryLocation W29549063121 @default.
• W2954906312 hasRelatedWork W1963740836 @default.
• W2954906312 hasRelatedWork W1971531287 @default.
• W2954906312 hasRelatedWork W1985107291 @default.
• W2954906312 hasRelatedWork W1992553889 @default.
• W2954906312 hasRelatedWork W1999105532 @default.
• W2954906312 hasRelatedWork W2020888164 @default.
• W2954906312 hasRelatedWork W2021776486 @default.
• W2954906312 hasRelatedWork W2061511993 @default.
• W2954906312 hasRelatedWork W2069138894 @default.
• W2954906312 hasRelatedWork W2081962373 @default.
• W2954906312 hasRelatedWork W2118809849 @default.
• W2954906312 hasRelatedWork W2155467782 @default.
• W2954906312 hasRelatedWork W2189159471 @default.
• W2954906312 hasRelatedWork W2327166423 @default.
• W2954906312 hasRelatedWork W2363714682 @default.
• W2954906312 hasRelatedWork W2417267401 @default.
• W2954906312 hasRelatedWork W2801045871 @default.
• W2954906312 hasRelatedWork W2915191076 @default.
• W2954906312 hasRelatedWork W3044863559 @default.
• W2954906312 hasRelatedWork W3047091817 @default.
• W2954906312 hasVolume "27" @default.
• W2954906312 isParatext "false" @default.
• W2954906312 isRetracted "false" @default.
• W2954906312 magId "2954906312" @default.

• next